FATE
Fate Therapeutics Inc
2.30$
-4.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +128.2% | -63.6% | -100.0% | – | +81.1% | -6.7% | +15.4% | +125.3% | +194.3% | +77.7% | +72.4% | -34.0% | -78.5% | -51.2% | |
| – | -13.0% | +0.1% | +36.9% | +20.8% | +33.2% | +29.9% | +63.1% | +56.7% | +43.1% | -95.3% | +135.2% | +1,042.5% | -24.6% | -89.1% | |
| – | -897.4% | – | – | – | – | – | – | – | -981.9% | – | +92.6% | -197.3% | – | – | |
| – | +21.7% | +0.1% | +36.9% | +20.8% | +33.2% | +29.9% | +63.1% | +56.7% | +43.1% | +71.6% | +48.7% | -46.1% | -21.8% | -20.1% | |
| – | -8.2% | +57.0% | +27.6% | +22.2% | -4.2% | +19.8% | +33.1% | +49.5% | +43.4% | +69.1% | +46.9% | -3.3% | -8.9% | -37.3% | |
| – | +12.2% | +14.9% | +33.6% | +21.3% | +20.4% | +27.1% | +55.4% | +55.1% | -69.6% | +687.7% | +51.6% | -76.1% | +8.8% | +34.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +283.5% | +63.4% | -31.0% | +304.4% | -26.3% | -22.5% | +33.8% | +3.3% | +37.0% | +89.2% | +28.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +283.5% | +63.4% | -93.3% | -1,377.4% | – | – | +637.4% | -120.1% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.